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he International Longevity Center and
The Ellison Medical Foundation, joined
by the Kronos Longevity Research
Institute and the Institute for the Study
of Aging, developed a workshop at Canyon
Ranch Health Resort, where we assembled some
of America’s leading biologists and clinicians
interested in aging to consider what we presently
know about putative biomarkers of aging from
rodents to man. Our goals were to come to a 
consensus, construct an agenda for future
research, and make appropriate recommendations
to policy-makers and the public-at-large.
These efforts are extremely important because of
well-publicized claims that the means exist to
directly intervene in aging processes. Obviously,
to verify such claims and test interventions 
experimentally it will be necessary to have proven
indicators which can monitor the aging processes,
just as pressure readings are used to monitor 
cardiovascular health.
These con s i d e ra t i ons foll ow a significant scientific
heritage which has resulted in an attempt to 
separate the normative, multi-causal processes 
of aging from diseases and other factors. It is
understood that chronological age remains the
most valid, if imperfect, biomarker of aging,
and that aging per se is a risk factor for a variety
of diseases, largely the polygenic conditions of 
late life such as Alzheimer’s disease, cancer and 
coronary heart disease.
However, it is self-evident that chronological age 
cannot be used as a biomarker in the sense
described above, because any intervention that is
successful in slowing the aging process will, by
design, result in asynchrony between biological
and chronological age.
These thoughts proved critical to the results of
the workshop. The biologists attending were able
to describe in extraordinary detail the failure as
yet to find validated biomarkers of aging in either
rodents or man. At the same time, the clinicians
were able to identify disease markers, risk factors
and functional measures that show dramatic 
correlations with longevity and quality of life.
Aging processes are manifest in the famous
G om p e rtz Curve, d e s c ribed in 1825 by a Lon d on
a c t u a ry, Benjamin Gom p e rt z . It shows the rise in
the “f o rce of mort a l i ty ” with the passage of time.
This important observ a t i on demon s t rates pro-
f o u n dly why it is necessary to provide major fund-
ing for studies at the molecular and cellular leve l
so that we may better understand what within 
our bodies incre a s i n g ly predisposes us to disease,
d i s a b i l i ty and ultimately death as we grow older.
At the same time, at an accelerated pace in the
last half century, we have learned about many
factors that adversely affect health, longevity and
quality of life.The ability to recognize disease
markers, risk factors and measurable functional
activities offers enormous power to the clinician.
Thus, the workshop report that follows is divided
into two parts. First, the biology of aging and 
the studies of biomarkers are described. Reasons
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are given why there is no validity to current
claims that a person’s “real age” can be measured,
and it is emphasized that such services should 
not be marketed to the unwitting public.
The second part describes some varied disease
markers, risk factors and functional measures
which do offer useful information to clinicians,
and can help people alter their lifestyles 
to maintain or improve their health. These 
measures are critical “wake-up calls” to promote
health and avoid unnecessary illness. n
vINTRODUCTION
W
hat biological changes take place as we
age? Efforts by scientists to uncover
the biomarkers of aging, that is,
the normal phenomena of growing
old, and to separate these inevitable physiologic
changes from diseases and other factors have
yielded tantalizing clues but few definitive
answers. We know that there are age-related 
risk factors for a number of diseases of older life,
such as Alzheimer’s disease. However, we do not
know if they are simply by-products of aging, or 
if they are an essential component of the aging
processes. Nor do we know how long and how
well physiological functions can be maintained
with increasing age. Finally, to date we cannot
separate genetics, lifestyles, the environment and
other idiosyncratic factors from age-related func-
tions that are universal.
The biological markers of diseases and factors
that make individuals vulnerable to certain 
diseases will enable clinicians to develop 
interventions to increase life expectancy and/or
enhance function in aging populations. Biological
markers of aging are also extremely important
because of well-publicized claims that the means
exist to retard or reverse aging processes.
Obviously, to verify such claims and test putative
interventions experimentally it will be necessary
to have proven indicators which can monitor
aging processes.
The International Longevity Center and The
E ll i s on Medical Fo u n d a t i on , joined by the Kron o s
Longevity Research Institute and the Institute for
the Study of Aging, held a workshop at Canyon
Ranch Health Resort and assembled some of
Am e ri ca’s leading biologists and clinicians intere s t e d
in aging to consider the question of whether 
biomarkers can be identified and used to measure
the physiological age of any individual within a
p o p u l a t i on ,g i ven emerging inform a t i on about aging
and new tech n o l o g i cal advances. Our goals were to
c ome to a con s e n s u s , c on s t ruct an agenda for future
research, and make appropriate recommendations
to policy-makers and the public-at-large.
A Definition of Aging
Our workshop report begins with a working 
definition of aging. Caleb Finch1 offers a good
overall definition: “A nondescript colloquialism
that can mean any change over time, whether
during development, young adult life,
or senescence. Aging changes may be good 
(acquisition of wisdom); of no consequence to
vitality or mortality risk (male pattern baldness);
or adverse (arteriosclerosis)”.
This report, however, focuses only upon the
adverse aspect of aging: the processes that 
progressively convert physiologically and 
c o g n i t i ve ly fit healthy adults into less fit individuals
with increasing vulnerability to injury, illness and
death. We are particularly interested in the
changes organisms undergo that adversely affect
their vitality and functional health over most of
the adult life span.
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1 Longevity, Senescence, and the Genome.Caleb E. Finch.
Chicago:University of Chicago Press,1990,671.
The Force of Mortality
While aging per se is a risk factor for a variety of
diseases, such as Alzheimer’s disease, cancer and
coronary heart disease, chronological age cannot
be used as a biomarker in the sense described
above, because any intervention that is successful
in slowing the aging processes will, by design,
result in asynchrony between biological and
chronological age.The famous Gompertz Curve,
described in 1825 by a London actuary, Benjamin
Gompertz, shows the rise in the “force of 
mortality” with the passage of time, which is the
manifestation of the underlying biology of aging.
Clinical Criteria for Biomarkers
In the absence of a more complete understanding
of the mechanisms of aging, clinicians would like to
have age-related biomarkers that have adequate
predictive value to provide information to their
patients. This information could help improve
organ function throughout the life cycl e, and re d u c e
unnecessary morbidity and premature mortality.
These biomarkers must be more than disease risk
factors, and represent individual indicators of
functional status. Clinicians prefer functional bio-
markers that relate to health expectancy, and that
1. Predict physiological, cognitive and 
physical function in an age-coherent way, and 
do so better than chronological age;
2. Predict the years of remaining good 
function, and the trajectory toward
organ-specific illness in the individual;
3. Are minimally invasive, and accessible 
to many individuals.
Several types of data could be utilized, including 
anthropometrical data, such as body mass index,
body composition, and bone density; functional
challenge tests, such as glucose tolerance test and
forced vital capacity; and physiological tests, such
as cholesterol/HDL.
These biomarkers could be measured in a large
group of people who have reached an age where
functional loss is known to occur most rapidly
(i.e., the 60 to 70 age group), but it would also be
useful to have data on younger adults as well.
Analyses would help to identify tests whose 
predictions were most accurate when matched
against actual functional outcome and morbidity
patterns. Tests with the best predictive value
would become functional biomarkers. They could
be used to test specific clinical approaches and
therapies that focus on improvement of physio-
logical, cognitive and physical functioning and
their relationship to functional age.The optimal
goal would be to obtain functional biomarkers
with which personalized medicine or other 
interventions could be developed, to effectively
reduce morbidity and improve organ-specific
function. Achieving this goal would delay the
necessity for costly hospitalization or social 
support of the aging population.
Ongoing Research
A number of studies have advanced our know l e d g e,
at the same time as they raise prov o ca t i ve question s :
• It is well-documented that growth hormone levels
fall with increasing age. Does this mean that 
low growth hormone levels accelerate aging? Not 
necessarily. It is equally plausible that falling
growth hormone levels may merely reflect other
aging processes which lead to dysregulation of 
a variety of cell s , i n cluding cells that secrete growt h
h o rm on e and those that regulate their secretion.
In fact, lower growth hormone levels may be an
i n d i cator of health. R e s e a rch findings on mice that
overproduce growth hormones indicate that 
they live only a short time, suggesting that growth 
h o rm one deficiency per se does not cause accelera t e d
aging, but that the opposite may be true2.
vi
2 Bartke A,Brown-Borg H,Mattison J, et al.2001. Prolonged longevity
of hypopituitary dwarf mice.Exp. Gerontol.36:21-28.
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• In 1935, Clive McCay first reported the effects of
aging and ca l o ric re s t ri c t i on in rats and mice. To d ay,
there is a body of literature which shows how
ca l o ric re s t ri c t i on alters age-related pathology 3,4.
• R e s e a rch suggests that the nervous system is a cri t i-
ca l factor in regulating the life span in laboratory
w o rms (nematodes), and that mu t a t i ons in a specific
gene can result in dramatic life span extension5.
We do not know if the nervous system of mammals
is similarly implicated, and if so, how this occurs.
• Studies have shown that chromosomes become
shorter each time a human cell divides, as their
ends are removed and not replaced6. These 
end regions, known as telomeres, should at least
be considered as a possible biomarker of human
aging. While telomere length is an indicator of
how many times a human cell has divided, rather
than a direct indicator of aging per se, it can 
be an indicator of functional age in certain human
cells or in tissues where replicative potential is
crucial to function, such as fibroblast involvement
in wound healing.
• Imaging techniques, including nuclear magnetic
re s onance (NMR) and positron emission tom o g ra-
phy (PET) , hold particular promise in ove rc om i n g
some of the technical problems associated with
studies of aging over extended periods of time 
( l ongitudinal studies). With the recent deve l o pm e n t
of high-resolution cameras capable of imaging
small animals, it is now possible to perform
relatively non-invasive studies on rats and mice as
t h ey age. Fu n c t i onal NMR can be used to study the
changes in anatomy and metabolic activity in the
b rain and other tissues during aging. PET imaging
may be used to study the neurochemical changes
that occur in the brain during aging, including
changes in neuro t ransmitter receptors and neuro -
t ransmitter syn t h e s i s .
Hurdles to Establishing Biomarkers
There are several hurdles to establishing informa-
tive biomarkers. One is the biological variation
between individuals, which makes generalizations
difficult. Another is the overlapping of aging 
and disease processes. Other hurdles include our
uncertainty about which age-related changes are
benign and which are indicators of pathology;
we do not have enough information to determine
if there is a point at which a process begins to 
do damage to the organism, and if so, the point 
at which it occurs; we do not know when 
to distinguish critical from non-critical damage.
Finally, and significantly, it is difficult to obtain
funding for this research.
Policy Implications
Obtaining support for a biom a rker re s e a rch agenda
p resents serious pro b l e m s . The re s e a rch pro g ra m
w h i ch was supported for 10 years (1988 – 1998) 
b y the NIA was accomplished through set-aside
funds and use of an ad hoc review process. Review
of applications for biomarker research by regular
Center for Scientific Rev i ew peer rev i ew groups 
at the NIH is not likely to result in sufficient 
numbers of funded applica t i ons to make substantial
progress in this area in the near future because
their focus is on the underlying mechanisms 
of diseases. Research on bio-markers does not
address this concern. Clearly, a non-traditional
long term source of funding is required, possibly
involving commercial or philanthropic sources 
of support. However, as long as the Food and
Drug Ad m i n i s t ra t i on has no pro g ram for ev a l u a t i n g
putative anti-aging interventions, commercial
organizations are unlikely to perceive sufficient
pay-off for funding such aging research.
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of aging in B6C3F1 h ybrid mice. J. Gerontol.54A:B466-477.
4 Lipman RD, Dallal GE,and Bronson RT. 1999b. Effects of genotype
and diet on age-related lesions in ad libitum fed and calorie-restricted 
F344,BN and BNF3F1 rats. J. Gerontol.54A:B478-491.
5 Larsen PL,Albert PS,and Riddle DL.1995.Genes that regulate both 
development and longevity in Caenorhabditis elegans.
Genetics 139:1567-1583.
6 Harley CB, Futcher AB,and Greider CW. 1990. Telomeres shorten 
during ageing of human fibroblasts. Nature 345:458-460.
7 Shelton, D. “Dipping into the fountain of youth,” American Medical News,
December 4,2000.
Public Education 
Leadership of the Am e ri can Academy of An t i -
Aging Medicine and others in the USA would have
us believe that aging is not inev i t a b l e, and that
“i m m o rt a l i ty is within our gra s p” 7. T h ey believe
that well-validated biom a rkers of aging already exist
w h i ch can be used to evaluate individuals at a cost
of seve ral thousand dollars per person , and that
these ev a l u a t i ons can then be used to design 
i n d i v i d u a l i zed anti-aging tre a t m e n t s . U n f o rt u n a t e ly
these treatments include some poorly validated
i n t e rve n t i ons such as improving anti-oxidant status
and horm one replacement thera p i e s , ( e . g. , g rowt h
h o rm on e, t e s t o s t e ron e, d e hyd ro e p i a n d ro s t e ron e
[ D H E A ] , m e l a t on i n , etc.)  
While it is seductive to believe that restoring
h o rm one levels back to levels that are produced in
young persons is a good thing, and although it is
t rue that horm one replacement trials have yi e l d e d
s ome positive short term re s u l t s , it is clear that 
n e g a t i ve side effects also may occur, in the form of
increased risk for cancer, cardiovascular disease,
behavior changes, etc. Estrogen replacement 
therapy in women has shown definite benefits,
especially for prevention of osteoporotic fractures.
Nonetheless, research on this hormone is still
underway, and some recent studies have raised 
“red flags” with re g a rd to the usefulness of estro g e n
for treating or preventing coron a ry heart disease.
The risk/benefit ratios for testosterone re p l a c e m e n t
and growth hormone treatment have not been
established in older persons. Finally, trials of
DHEA have failed to show significant cl i n i cal 
benefits in normal aging. Clinical trials to investi-
gate the risks and benefits of these and other
potential interve n t i ons are either still going on , o r
h a ve not yet provided definitive answers. The public
is advised to exercise caution in requesting these
popular anti-aging interventions until adequate
clinical trials have been completed and analyzed.
The participants of this workshop strongly
recommended continuing research on these and
other hormones, antioxidants and agents that 
may have favorable effects upon the promotion
of health, e.g., the possibility that some anabolic
hormones protect, if only for a short term,
against the frailties of old age. At the same time,
advancement of healthier lifestyles with attention
to diet, exercise, tobacco cessation and ear ly
identification of risk factors, measurements of
functional status and disease markers are desirable
and achievable goals. For example, it is important
to lower cholesterol levels through exercise or 
the use of pharmacological agents like statins,
and to detect hypertension and diabetes ear ly in
order to effect appropriate control and prevent 
the often lethal consequences of both.
Conclusion
E a rly identifica t i on of risk factors, m e a s u rements 
of functional status and disease markers are 
d e s i rable and ach i evable go a l s , and new studies are
advancing our understanding of factors that 
c on t ribute to health and lon g ev i ty, a m ong them
e xe rc i s e, s m oking cessation , n u t ri t i on ,
e nv i ronmental and genetic factors. At the same
t i m e, our ra p i dly aging population increases the 
re l evance of re s e a rch to find age-related biom a rk e r s .
Although a definitive panel of biom a rkers for
assessing phys i o l o g i cal age of individuals within a
p o p u l a t i on has not yet been ach i eve d , studies using
organisms in the labora t o ry continue to prov i d e
re s e a rchers with important data. The ultimate go a l
is to develop age-related biom a rkers to measure
i n t e rve n t i ons that may increase life expectancy and
enhance healthy aging for as long as possible. n
viii
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discussion about biomarkers of aging
immediately runs into some difficulty,
first because few people can agree on
a definition of aging, and second,
because different definitions of “biomarker” are
employed by basic and clinical scientists with 
different interests and backgrounds. Edward
Masoro pointed this out in 1988 when he wrote
that “there are two major reasons why there is 
controversy about the use of physiological systems
as biomarkers of aging: one relates to the lack of
k n owledge about the basic aging processes and the
other is the confusion about what a biomarker of
aging is designed to do” (Masoro, 1988). Leaving
aside for the moment the question as to whether
such barriers to biomarker development are
insurmountable, we must begin with a working 
definition of aging. One good overall definition is
that aging is “A nondescript colloquialism that
can mean any change over time, whether during
development, young adult life, or senescence.
Aging changes may be good (acquisition of
w i s d om ) ; of no consequence to vitality or mort a l i ty
risk (male pattern baldness); or adverse 
( a rt e ri o s cl e ro s i s)” ( Fi n ch , 1 9 9 0 ) . For the purp o s e s
of this discussion how eve r, we will focus upon the
adverse aspect of aging: the process that 
p ro g re s s i ve ly conve rts phys i o l o g i ca lly and cognitive ly
fit healthy adults into less fit individuals with
i n c reasing vulnera b i l i ty to injury, i llness and death.
We are particularly interested in the changes 
in an organism that adve r s e ly affect its vitality and
functions over most of the adult life span.
At the workshop, biomarkers of aging were
defined by participant Richard Miller as traits
which meet three criteria:
1.The biomarker should predict the outcome of 
a wide range of age-sensitive tests in multiple
physiological and behavioral domains, in an
age-coherent way, and do so better than
chronological age;
2. It should predict remaining longevity at an age
at which 90% of the population is still alive,
and do so for most of the specific illnesses that
afflict the species under study;
3 . Its measurement should not alter life expectancy
or the outcome of subsequent tests of other age-
s e n s i t i ve tests.
This definition provided a framework for the 
discussion at the workshop.
The second criterion implies that biomarkers are
likely to be measuring degenerative processes,
not just age-related change. Some effects of age,
such as experience and judgment, may be 
beneficial, but are unlikely to pass the second 
criterion. Others, such as gray hair or skin 
wrinkles, may themselves have little effect on
mortality risks, yet still serve as easily measurable
indices of underlying degenerative processes 
that do increase vulnerability.
A continuing controversy is whether there exist
processes of aging per se, which can be identified
and studied independently of age-related disease.
It is clear that there are age-related risk factors for
disease, and that these overlap with risk factors
for aging, but there is disagreement about whether
diseases to which older persons are vulnera b l e
should be con s i d e red mere ly by-products of aging,
or an essential component of the aging processes.
This seems to be primarily a semantic issue for
some, but a major question for others, and the
issue cannot be settled here. What is important is
how long and how well physiological functions
can be maintained with increasing age; whether
and what measurements can be done to assess 
this biologically, and in so doing obtain 
a multi-component physiological yardstick for
aging. Ultimately, the goal is to use this tool to
develop interventions that increase life expectancy
and/or enhance function in aging populations.
NIA-SPONSORED WORKSHOPS IN 1981 AND
1986, AND THE 1988-1998 BIOMARKERS 
INITIATIVE
This is at least the third workshop on Biomarkers
of Aging. In 1981 the National Institute on
Aging organized its first conference on nonlethal
b i o l o g i cal markers of phys i o l o g i cal aging. A secon d
workshop, also sponsored by the National
Institute on Aging (NIA), was held in 1986 in
Chicago, Ill. It was convened to discuss “strategies
for the conduct of biomarkers of aging research
prior to the initiation of a request for biomarker
research applications by the National Institute 
on Aging. The intent of the NIA was to generate
interest in biomarker research, update general
understanding of the biomarker concept, and
most important, solicit the advice of knowledge-
able scientists before issuing requests for research
applications in this area” (Sprott, 1988). Such a
request for applications was issued by the NIA in
1987, and applications were funded beginning 
in Fiscal Year 1988.The program was renewed
for five more years in 1993, and continued 
until 1998. Although the research was done on
genetically homogeneous strains of rats and mice,
the hope was that any panel that was developed
might also be relevant to human populations
which are genetically heterogeneous.
This 10-year initiative resulted in many publica t i on s ,
but it appears that a definitive panel of biom a rk e r s
for assessing the phys i o l o g i cal age of individuals
within a population was not achieved. A series of
seven papers was published in the November and
December, 1999 issues of the Journal of
G e ron t o l o gy (v. 5 4 A , p. B 4 6 4 - 5 6 6 ) . These re p o rt s
a re among the first to summari ze the results of this
broad initiative (Sprott, 1999). They include a 
comprehensive summary of the age-related 
pathology observed in the rats and mice used in
this study and how caloric restriction alters it
(Lipman et al., 1999a, 1999b), as well as an 
extensive characterization of growth and survival
ch a ra c t e ristics of the various mouse and rat models
used (Tu rt u r ro et al., 1 9 9 9 ) . The remaining four
papers describe a vari e ty of attempts to identify
and/or validate various biom a rkers of aging, s u ch as
a g e - related changes in the potential for cell pro l i fe r-
ation (Wolf and Pendergrass, 1999), changes in 
circulating hormones (Sonntag et al., 1999) and
brain MAPK signaling (Zhen et al., 1999),
and behavioral changes (Mark owska and Bre ck l e r,
1 9 9 9 ) . The work supported by this NIA biom a rk e r
i n i t i a t i ve thus added to the litera t u re documenting
the effects of aging and caloric restriction on a 
variety of interesting traits, but did not produce
c onvincing evidence that these candidate biom a rk e r s,
s e p a ra t e ly or in com b i n a t i on , p rovided inform a t i on
about the “phys i o l o g i cal age” of the individual upon
whom the measurements were done.
2000 WORKSHOP
The purpose of this most recent workshop was 
to re-visit the question of whether biomarkers 
of aging can be identified and used to measure
physiological age of any individual within a 
2
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3population, given emerging information about
aging and new technological advances.
The meeting was organized by Robert Butler 
and Richard Sprott, and the participants included 
several individuals involved in the 1988-1998 
initiative (Richard Feuers, Michael Forster,
William Sonntag, Norman Wolf),
several gerontologists not involved in the 
initiative (Jeffrey Bland, Michael Hewitt,
Gerald McClearn, Richard Miller, James Nelson,
Arlan Richardson and Richard Weindruch),
and several clinicians (Howard Fillit, Mitchell
Harman, Mark Hyman, Kathleen Johnson
and Evan Kligman).
Their discussions centered on the 
following issues:
• What are the hurdles to evaluating and
validating biomarkers of aging?
• Is the central nervous system a pacemaker 
of aging?
• Development of a research agenda
• Identification of possible interventions 
that might alter aging and delay
age-dependent pathology
• Overlap between “biomarkers of aging”
and “indicators of functional status”
• Policy implications
• Public education
What are the hurdles to evaluating 
and validating biomarkers of aging?
There are several hurdles to establishing informa-
tive biomarkers. One is the inter-individual 
and measurement variations which could be large
enough to obscure differences due to aging-
related change. Another is the overlapping of
aging and disease processes as sources of change.
Other hurdles include our uncertainty about 
which age-related changes are benign and which
are indicators of adverse events; our lack of 
information about whether there are damage
thresholds which only have a significant effect
once these thresholds are breached, and if so 
what these thresholds are; our need to distinguish 
critical damage from non-critical damage 
(e.g., mutations need not lead to amino acid
changes in proteins, and not all oxidized side
chains in proteins will have functional 
consequences). Finally, there is the practical 
hurdle of obtaining support for the research
needed; grant applications, including proposals 
to identify and validate biomarkers are unlikely
to be enthusiastical ly reviewed by the usual 
peer review process, because of the perceived 
non-mechanistic nature of such research.
Is the central nervous system a 
pacemaker of aging?
Several recent publications describing research on
Caenorhabditis elegans (C. elegans) suggest that the
nervous system is a critical factor in regulation of
life span in nematodes. Mutations in the daf-2
gene in nematodes can result in dramatic life span
extension (Larsen et al., 1995). The daf-2 gene
codes for an insulin receptor-like protein (Kimura
et al., 1997; Wolkow et al., 2000) recently showed
that restoring daf-2 function in the neurons 
alone was sufficient to specify wild type life span,
whereas a similar intervention in muscle or
intestine had no such effect. The nervous system
in nematodes has also been implicated in life span
regulation by Apfeld and Kenyon (1999), who
showed that mutations blocking sensory signal
transduction extend nematode life span. Ailion
et al. (1999) showed that mutations in unc-64
extend nematode life span, and that the site 
of action of unc-64 is neuronal, and through the
insulin receptor pathway. Finally, overexpression
of human Cu/Zn superoxide dismutase (SOD-1)
ILC Workshop Report: Biomarkers of Aging
in motor neurons in fruit flies also extends life
span (Parkes et al., 1998). Thus, this series of
findings clearly implicate the nervous system in
life span regulation in these two invertebrate 
systems, but the question remains whether, and
how, the mammalian nervous system might be
similarly implicated.
In the search for meaningful biomarkers of aging,
the mammalian neuroendocrine system presents 
a more confusing picture. One interesting place 
to look might be regulation of either growth 
hormone (GH) production or function, because it
is well-documented that circulating GH levels fall
with increasing age, which suggests that low GH
levels might accelerate aging. However, it is
equally likely that falling GH levels may merely
reflect one or more underlying aging processes
which lead to dysregulation of differentiated 
cells of various types, including those that secrete,
and those that regulate the secretion of GH.
Moreover, there are several lines of evidence that
suggest that GH deficiency per se is not a cause
of accelerated aging, and that the opposite 
may be true.These include the following: mice
overproducing GH are short-lived (Bartke et al.,
2001); mice selected for slow growth rates in the
first two months of life are relatively long-lived
(Miller et al., 2000); dwarf mutant mice (df and
dw mutations) with defects in GH, prolactin,
and thyroid stimulating hormone production,
have extended longevity (Brown-Borg et al.,
1996; Miller, 1999), as do GH receptor-deficient 
mice (Coschigano et al., 2000); and the inverse
correlations between body size and life span 
in mice and dogs (Miller, 1999).These df and dw
mice have defects in pituitary development, and
as a result exhibit multiple endocrine deficiencies.
It is not known which deficiency, if any, is critical
for life span extension, but it is worth noting 
that GH receptor-deficient mice are neither 
thyroid nor prolactin-deficient.
One possible new tool for looking at age-related
changes in brain function is gene expression
microarray technology. Lee et al. (2000) have
reported a first experiment to investigate such
changes in mouse cerebellum and neocortex using
arrays representing 6,347 genes. Their general
conclusion was that aging-related changes in
these tissues are indicative of increased oxidative
stress and an inflammatory response with 
increasing age. However, it is too early to know
how useful microarrays will be in identifying
informative transcriptional biomarkers of 
either brain function or aging, and if they are,
which genes will be critical. Finally, the use of
neuroimaging technologies is also promising 
for the development of brain-related biomarkers.
Imaging techniques can be used to estimate
changes in brain activity, and thus indirectly cell
number. Significant reduction of cell number in
brain, or other critical tissues, might predict 
physiological age and mortality. These new tools
will be briefly addressed in the next section.
Development of a Research Agenda
The 1988-1998 NIA Biomarkers of Aging
Initiative was based on the idea that biomarkers
would be modulated by caloric restriction (CR)
intervention. It still seems reasonable that at least
some physiological indicators of aging may be 
so modulated, as CR remains the only known
intervention to reliably retard aging and extend
maximum life span in a wide variety of species
(Masoro, 2000). Of some relevance is the recent
observation that the expression of only about two
per cent of mouse genes in post-mitotic tissues 
are changed by two-fold or more during aging 
in mice, and that many, but not all, of these 
age-related changes are reversed by CR (Lee 
et al., 1999; Lee et al., 2000). In fact, incomplete
reversal of age-related changes in gene expression
by CR may provide insights into which changes
are critical in aging (Han et al., 2000).
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5If one assumes that genes whose expression
changes with age are likely to be associated with
informative biomarkers of aging, then it becomes
important to ask what is the potential for gene
expression microarray analysis in biomarker
research using mice? Such an approach might
require two stages (Miller et al., 2001).The first
stage would be to test all known mouse genes for
changes in expression greater than some arbitrary
amount, say 50% or 100% change, using enough
mice to achieve statistical significance. Further
levels of complexity of such an undertaking are
t h a t , 1) many genes are expressed in a tissue-specific
manner, so that multiple tissues would have to be
examined separately; 2) it will be necessary to 
follow the sequence and patterns of changes ove r
a range of ages, rather than to simply examine
animals arbitrarily defined at two age points as
young and old; and, 3) it will be necessary to
examine changes in several strains of mice,
because some apparent aging changes may turn
out to be strain-specific. Although the complete
sequence of the mouse genome is not yet known,
the sequence is expected to become available in 
the next 2-3 years. As various DNA-based
microarray technologies improve, there is
optimism that changes of as little as 20% may be
reliably detected (personal communication,
Minoru Ko, Gerontology Research Center,
Baltimore, MD). Once this has been done, the
expression of all qualifying genes, that is, genes
showing statistically significant age-related
changes of at least some minimum magnitude 
in more than one strain, would need to be 
re-examined as a function of tissue and at a vari e ty
of ages, and these changes related to development
of pathology, to identify which changes in gene
expression might be informative. Unfortunately
the invasive nature of such an experiment 
precludes its use in longitudinal studies for most 
t i s s u e s , so the remaining life span of the individual
mouse could not be determined. However, cross
sectional results should identify some small
number of genes whose expression changes 
substantially enough with increasing age to be 
a putative biomarker of the condition of some
physiologically important system(s).
Just how many genes will be identified in this 
way depends upon the sensitivity and reliability
of the microarray system used, and the amount of
biological variation inherent in the expression
of each gene (Dozmorov et al., 2001). It will also
depend on the percent change and statistical 
significance limits imposed in the first phase. The
results of Lee et al. (1999, 2000) suggest that 
the theoretical maximum number of mouse genes
would be no larger than about 1,000 genes for 
any given tissue, assuming there is a total of 
about 50,000 mouse genes and that both increases
and decreases are relevant. Major caveats to this
approach include the potential high variability
a m ong results obtained from genetica lly hetero g e-
neous individuals; the possibility that highly
re l evant “age indica t o r s ” m ay lie below the detection
limit in such an analysis; and the invasive
sampling procedure required. Nevertheless,
DNA-based microarray technology is potentially
very powerful, and as the reliability and sensitivity
of the technology improves, it should eventually
become useful in evaluating the physiological 
status of aging animals and/or humans. Future
development of protein-based microarray tech-
nologies for screening the amount and activity of
specific proteins may turn out to provide an even
better approach (MacBeath and Schreiber, 2000).
The ca veats discussed above apply as well to 
the validation of any potential biom a rker of aging.
H ow eve r, e a ch type of potential biom a rker will
also present its own unique hurdl e s .T h e re is 
no doubt that aging and age-related pathology are
a c c ompanied by ox i d a t i ve damage, but it is less
clear which ox i d a t i ve modifica t i ons are cri t i ca l .
The presence of 8-hyd roxyguanine in DNA and
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amino acids with ox i d i zed side chains in pro t e i n s
a re genera lly accepted biom a rkers of ox i d a t i ve
stress, but it is not clear whether global
m e a s u rements of ox i d a t i ve stress are sufficiently
i n f o rm a t i ve to provide biom a rkers of aging.
Techniques for measuring levels of 8-hydroxygua-
nine in DNA are mu ch improved over those used
5-10 years ago, but it is not yet clear how good an
i n d i cator of aging they may be. Pe ro et al. ( 2 0 0 0 )
have suggested that as crude a measurement as
serum protein sulfhydryl groups correlate with
mammalian life span. A more promising appro a ch
might be to identify proteins which are essential
for a critical function, such as ATP production,
and may become rate-limiting through oxidative
or other damage. Two examples of this are
cis-aconitase (Yan et al., 1997), and adenine
n u cleotide tra n s l o case (Yan and Soh a l , 1 9 9 8 ) . Tw o
other candidates are glutamine synthetase (Carn ey
et al., 1991), which detoxifies ammonia while 
low e ring glutamate levels in the bra i n , and poly
A D P - ribose polym e rase (Pe ro et al., 2 0 0 0 ) , w h i ch
is essential for DNA repair in eukaryotic sys t e m s .
If aging is at least partially reflected in a loss of
ability to maintain homeostasis, then a decrease in
one or more stem cell populations might predict
there is less life span remaining, especially if these
stem cells are critical for replacement of cells lost
through apoptosis. However, no direct evidence
exists to suggest that this is so, and good methods
for isolating and characterizing stem cells are not
yet available. In a similar vein, some measure of
DNA repair capacity might predict the ability to
maintain genetic stability, and thus homeostasis.
Although DNA damage is most frequently
associated with cancer risk, a defective Werner’s
syndrome gene leads to genetic instability and
some aspects of aging prematurely, as well as
increased tumorigenesis (Oshima, 2000).The
Werner’s syndrome gene product may very well be
involved in DNA repair as it codes for both DNA
helicase and 3’ exonuclease activities, and loss 
of these two activities appears to be related to
premature aging.
Studies have shown that chromosomes become
shorter each time a human cell divides, as their
ends are removed and not replaced. (Harley et al.,
1990) These end regions, known as telomeres,
should at least be considered as a possible
biomarker of human aging. While it is clear that
telomere length is an indicator of how many
times a human cell has undergone cell division
rather than a direct indicator of aging per se, it
might be informative as an indicator of functional
age in certain human cells or tissues where
replicative potential is crucial to function,
e.g., fibroblast involvement in wound healing.
However, because of their initially long telomere
length, rodent cells appear not to rely on telomere
length-induced replicative senescence to limit 
the number of cell divisions available (Shay and
Wright, 2001).Thus, attempting to validate
telomere length as a biomarker in rodent cells
may not be useful in developing a human 
biomarker for aging. However, there are reports
that telomere length does decrease and might 
be correlated with aging in some rat tissues
( Jennings et al., 1999; Kajstura et al., 2000).
A major problem with the above suggestions 
is that most require some invasive sampling, and
thus are likely to violate criterion number three.
Non-invasive sampling and measurements are
much more desirable, which would limit 
e x p e ri m e n t a t i on to blood samples, a n t h ro p om e t ri c
measurements, imaging techniques, or possibly
skin, muscle or fat biopsies. Another problem
is that they depend on correct guesses about 
candidate biomarkers, which earlier experience
suggests have only a limited chance of 
success. A real biomarker validation program
could be constructed by encouraging a substantial
number of laboratories (perhaps 10?) to measure
6
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7ove rlapping sets of 10-25 bioch e m i ca l , phys i o l o g i ca l
or psychological traits, depending on the expertise
of the laboratory, in several hundred genetically
heterogeneous mice at several ages, and coupling
these measurements with data on survival and
pathology assessment at death. These data should
be provided in a form suitable for statistical 
analysis to identify significant correlations among
age-sensitive traits, and predictive value for life
span and a variety of age-related diseases. Pre-
existing data sets like the Baltimore Longitudinal
Study of Aging and the Framingham longitudinal
studies should also be mined for analogous traits
in humans. Also, genetic studies on centenarians
may increasingly identify both favorable 
and unfavorable alleles for promoting long life
(Perls et al., 2000; Perls, 2001). These combined
approaches should identify some promising
biomarkers to be validated prospectively in 
human studies.
M e re ly showing that a given assay changes with
a g e, and thus distinguishes most old people from
most young people, is not sufficient to qualify 
a test as a biom a rk e r. T h e re are, and will continue 
to be, m a ny candidates for biom a rk e r s , but the 
real ch a llenge in developing a pro d u c t i ve re s e a rch
agenda is to validate some of these as true 
b i om a rk e r s . The test in question must divide 
people (or mice) of a given age into groups that
d i f fer pre d i c t a b ly in a wide range of other 
a g e - s e n s i t i ve traits (Mill e r, 1 9 9 7 ) .
Imaging techniques, including nuclear magnetic
resonance (NMR) and positron emission
tomography (PET), hold particular promise 
in overcoming some of the technical problems 
associated with longitudinal studies of aging.
With the recent development of high-resolution
cameras capable of imaging small animals, it 
is now possible to perform relatively non-invasive
studies on rats and mice as they age. Functional
NMR can be used to study the changes in 
anatomy and metabolic activity in the brain and
other tissues during aging. PET imaging may
be used to study the neurochemical changes that
occur in the brain during aging, including
changes in neurotransmitter receptors and 
neurotransmitter synthesis. A drawback of these
procedures in animal studies is the need to 
anesthetize the animals, and proximity to the 
necessary imaging facilities. An exciting new use
for PET imaging is the non-invasive imaging 
of reporter gene expression in living animals
(Herschman et al., 2000). Using PET reporter
genes and PET reporter probes investigators can
examine the transcriptional activity and activation
of promoters incorporated in transgenes or in
viral vectors. One enormous potential advantage
of non-invasive imaging of gene expression in
living animals is that repeated analysis of gene
expression could be made during experimental
manipulations. With the rapid advancements 
in this area, it is quite possible that imaging 
techniques will become available that will allow
scientists to monitor non-invasively, in real time,
the levels of reactive oxygen species in tissues 
and groups of cells. This technology is becoming
extremely important in aging research, especially
in studies with human subjects (Bookheimer 
et al., 2000; Small et al., 2000).
Identification of Possible Interventions
One of the major reasons for identifying and 
validating biomarkers would be to obtain 
endpoints for testing possible interventions in a
model system to retard, prevent, or even reverse
adverse age-related changes, as discussed by
Warner et al. (2000).These authors concluded
that a comprehensive panel of informative
endpoints in mice might include survival curves;
pathology assessment; non-invasive endpoints
such as locomotion, cognitive function, physio-
logical function (e.g., T-lymphocyte subsets);
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biomarkers of oxidative stress; other measures 
of resistance to stress; and gene expression
microarray analysis. However, first these 
endpoints need to be validated as to their value 
as true biomarkers in such a testing program.
Although antioxidant interventions continue to
be a favorite choice for testing, the success of 
such interventions has been mixed despite some
epidemiological data suggesting that dietary
vitamin E supplementation reduces the risk of
heart disease in men and women (Rimm et al.,
1993; Stampfer et al., 1993). Life span extension
has been observed in invertebrate systems overex-
pressing Cu/Zn superoxide dismutase (SOD)
(Parkes et al., 1998; Sun and Tower, 1999), but
this is not a viable human intervention. However,
Melov et al. (2000) have recently shown that a
SOD/catalase mimetic called EUK-134, when
added to the diet, does extend life span in 
nematodes, and using this compound in humans
might be possible. In con t ra s t , R i ch a rd We i n d ru ch
reported at the workshop that in his research
laboratory no life span extension occurred in male
middle-aged mice treated with a variety of 
compounds including a-lipoic acid, N-acetyl
cysteine, vitamin E, coenzyme Q10, melatonin,
and aminoguanidine, alone and in various
combinations. However, these negative results 
do not preclude the possibility that some of these
interventions might retard one or more organ-
specific aging processes in either mice or humans.
A ve ry recent paper suggests that genetica lly -
induced re d u c t i on of the tra n s p o rt of dica rb ox yl i c
acids, key intermediates in the citric acid cycle,
appears to slow aging in fruit flies (Rogina et al.,
2000). This mutation could be mimicking one
aspect of ca l o ric re s t ri c t i on , w h i ch could possibly
also be accomplished ph a rm a c o l o g i ca lly by using an
inhibitor of this dica rb ox ylic acid tra n s p o rt enzym e .
It is widely accepted that mitochondria are the
chief source of reactive oxygen species (ROS) 
in eukaryotic cells. Although it is not known
exactly how much superoxide anion is generated
by mitochondria during normal oxidative
metabolism, estimates are in the range 1% - 5% 
of the total oxygen consumed by the electron
transport system. This superoxide is converted 
to hydrogen peroxide by the mitochondrial 
Mn-superoxide dismutase. However, hydrogen
peroxide itself is a reactive compound, and may
leak into the cytoplasm, where it can peroxidize
fatty acids in membranes or be converted to
hydroxyl radical which rapidly damages proteins
and nucleic acids.The enzyme catalase is
necessary to convert this hydrogen peroxide into
harmless oxygen and water. Also relevant 
is the discovery that cytochrome C leaking from
damaged mitochondria is a triggering event for
apoptosis (Green and Reed, 1998).This sequence
of events is particular ly damaging in post-mitotic
tissue, where the potential for replacement of 
lost cells is extremely low. Thus, any intervention
that can block this sequence of adverse events 
as close to the starting point as possible (i.e., the
generation of superoxide anion by the electron
t ra n s p o rt sys t e m ) , should be con s i d e red a prom i s i n g
candidate to reduce age-related pathology and
delay aging. An instructive line of research would
be to elucidate how birds, with their very high 
metabolic rate, manage this potential oxidative
stress problem (Holmes and Austad, 1995).
Blocking apoptosis has also partially ameliorated
pathological consequences in animal models of
neurodegenerative disease and stroke (Friedlander
et al., 1997; Kang et al., 2000), although 
apoptosis may also have positive roles during
aging (Warner et al., 1997).
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9Overlap between biomarkers of aging and 
indicators of functional status
As defined earlier, biomarkers of aging can be
interpreted to mean a parameter or set of 
parameters that define characteristics related 
to increasing mortality with chronological age.
Another interpretation could relate to a set 
of parameters that define functional ability
(i.e., physiological, cognitive and physical
function), and its relationship to morbidity and
mortality with chronological age. While the 
first definition seems best suited for establishing
research approaches toward the understanding 
of the fundamental physiological and metabolic
processes of aging, this second definition is 
applicable to the need of the clinician who 
manages patients requesting recommendations
and/or therapies to reduce their morbidity
and extend longevity. It is recognized that both 
definitions have value when applied in their
respective settings, but are likely to converge with
one another as the basic mechanisms of aging 
in humans become better established. It is 
reasonable to assume that real biomarkers of
aging will also correlate with risks for multiple
degenerative changes and functional decline 
in a variety of species.
In the absence of a more complete understanding
of the mechanism of aging, clinicians would like
to have age-related biomarkers that have adequate
predictive value to provide qualified information
to their patients to help improve organ-specific
function throughout the life cycle, and reduce
unnecessary morbidity and premature mortality.
These biomarkers might be more than disease
risk factors, and represent individual indicators of
functional status. Clinicians might prefer a panel
of functional biomarkers of aging that relate to
health span. In concordance with Dr. Miller’s
criteria, these biomarkers should:
1. Predict physiological, cognitive and physical
function in an age-coherent way, and do so 
better than chronological age.
2. Predict the years of remaining functionality,
and the trajectory toward organ-specific illness
in the individual.
3. Be minimally invasive, and accessible 
to many individuals.
T h e re are seve ral types of data that could
c onstitute a panel of functional biom a rkers of
a g i n g, i n cluding anthro p om e t ric data (body mass
i n d e x , body com p o s i t i on , b one density, e t c . ) ,
f u n c t i onal ch a llenge tests (glucose tolerance test,
f o rced vital ca p a c i ty, e t c . ) , phys i o l o g i cal tests 
( ch o l e s t e ro l / H D L , g lyc o s ylated hemoglobin,
h om o cys t e i n e, e t c . ) , g e n omic and pro t e omic tests.
Such a set of putative functional biomarkers 
of aging could be measured in a large group of
adults who are at an age where functional loss 
is known to occur most rapidly, such as in the 
60 to 70 age group, but it would also be useful 
to have data on younger adults as well. Statistical
evaluation of the data using cluster analysis,
pattern recognition, and principal component
analysis would help to identify tests that had the
greatest predictive value when matched against
functional outcome and morbidity patterns.
Those with the highest predictive value would be
defined as functional biomarkers of aging. These
parameters could then be used to test specific
clinical approaches and therapies that focus 
on improvement of physiological, cognitive and
physical functioning and their relationship to
functional age. The optimal goal would be 
to obtain a panel of functional biomarkers of
aging that could be used to develop personalized
medicine or other inter ventions which effectively
reduce morbidity and improve organ-specific
function, thereby delaying the necessity for 
costly hospitalization or social support of the
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aging population. At least one such attempt 
to do this has already been reported 
(Hochschild, 1990).
Policy implications
How can support be obtained for a biomarker
research agenda? The research program supported
for 10 years (1988-1998) by the NIA was 
accomplished through set-aside funds, and use of
an ad hoc review process. Review of applications
for biomarker research by regular Center for
Scientific Review peer review groups at the NIH
is not likely to result in enough funded 
applications to make substantial progress in this
area in the near future because of the perceived
non-mechanistic character of the research.
Clearly, a non-traditional long term source of
funding is required, possibly involving commercial
or philanthropic sources of support. However,
as long as the Food and Drug Administration has
no program for evaluating putative anti-aging
interventions, commercial organizations are
unlikely to perceive sufficient pay off-for funding
such aging research.
Some biom a rk e r - re l evant re s e a rch is funded by
NIA-funded centers, s u ch as the Nathan Sh o ck
C e n t e r s , for example, in their gene expre s s i on
m i c ro a r ray and animal model deve l o pment core s ,
but none of these Centers has an ove rt com m i t-
ment to biom a rker re s e a rch per se at this 
t i m e . M o re ove r, re s e a rch at these Centers remains 
m o re focused on basic mechanisms than on
human phys i o l o gy.
Public education 
There are individuals and organizations in the
USA who would have us believe that aging is not
inevitable, and that “immortality is within our
grasp” (Shelton, 2000). These same individuals
b e l i eve there already exist well-validated biom a rk e r s
of aging which can be evaluated at a cost of 
several thousand dollars per person, and that
these evaluations can then be used to design 
individualized anti-aging treatments.
Unfortunately these treatments include some
poorly validated interventions such as improving
anti-oxidant status and hormone replacement
therapies, including growth hormone,
testosterone, dehydroepiandrosterone (DHEA),
melatonin, etc. Although it is possible that by
p roviding evidence of dys re g u l a t i on of diffe re n t i a t e d
cell function, age-related hormonal changes may
serve as useful markers of physiological aging, this
has not been demonstrated experimentally for
either humans or animals. While it is seductive to
believe that restoration of hormone levels back to
levels that exist in young persons should be a
good thing, and although hormone replacement
trials have yielded some positive results (at least in
the short term), it is clear that negative side
effects also may occur, in the form of increased
risk for cancer, cardiovascular disease, behavior
changes, etc. Estrogen replacement therapy in
women has been shown to have definite benefits,
especially for prevention of osteoporotic fractures,
although some recent studies have raised “red
flags” with regard to the usefulness of estrogen for
treating or preventing coronary heart disease.The
risk/benefit ratios for testosterone replacement
and GH treatment have not been established in
older persons. Finally, trials of DHEA have failed
to show significant clinical benefits in normal
aging. Clinical trials to investigate the risks and
benefits of these and other potential interventions
are either still going on, or have not yet provided
definitive answers, and the public is advised to 
be cautious in requesting these popular anti-aging
interventions until adequate clinical trials have
been completed and analysed.
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As important as reporting promising findings 
in biomarker research is demonstrating when
popular “anti-aging” interventions have no effect,
or worse, when they have adverse effects.The
majority of participants in this workshop
expressed concern about the use of human growth
hormone, DHEA, melatonin, various antioxidants
and other agents that are claimed to retard or
reverse aging, especially given the fact that there
are currently no valid biomarkers of human aging.
On the other hand, the participants strongly
recommended continuing research on these and
other hormones, antioxidants and other agents
that might have favorable effects upon the 
promotion of health (e.g., the possibility that
some anabolic hormones might protect, if only
for a short term, against the frailties of old age).
Concern was expressed over the Dietary
Supplement and Health Education Act of 1994.
It opened the doors to a multi-billion dollar
health food store and Internet business that 
promotes a variety of agents that are claimed to
retard aging and overcome age-related diseases.
There is no FDA supervision even to assure the
purity of substances offered for sale, let alone
their effectiveness and dangers.
The concept of “anti-aging medicine” contrasts
with modern gerontology which distinguishes
between aging as natural phenomena and 
diseases, and the role of aging per se as a risk 
factor for diseases. Anti-aging medicine is not an
established specialty although it is being hailed 
as such. Many lucrative medical practices have
emerged which operate outside of the formal
insurance system. Systems that suggest they have
the ability to measure biomarkers of aging and
that they possess the means to favorably affect
them are not scientifically-based. These 
practitioners of anti-aging medicine should be
distinguished from mainstream clinicians 
who are concerned with health promotion and 
disease prevention.
Nevertheless, advancement of more favorable
lifestyles with attention to diet, exercise, tobacco
cessation and early identification of risk factors,
measurements of functional status and disease
markers is a desirable and achievable goal.
For example, it is important to lower cholesterol
l evels through exe rcise or the use of ph a rm a c o l o g i ca l
agents like statins, and to detect hypertension
and diabetes early in order to effect appropriate
control and prevent the often lethal consequences
of both. n
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his publication is part of the Canyon
Ranch Series, which focuses on bringing
to public attention some of the significant
ongoing work being done by researchers
in a variety of fields to improve the health and
longevity of individuals as they grow older.
Maintaining Healthy Lifestyles discusses what
social and behavioral scientists, and behavioral
health experts have learned about helping people 
control the greatest risk factors facing Americans 
today: tobacco, a sedentary life and poor diet.
Achieving Cognitive Vitality with Aging brings
yet another dimension to lifestyle modification,
demonstrating that not only physical status, but
also mental status is subject to modification.
It must be strongly emphasized that the claims 
of a “specialty” area of medicine known as 
“anti-aging medicine” are not rooted in academic
medicine and science, and that anti-aging medicine
is not a recognized specialty. Further, substances
recommended by “anti-aging” doctors, such as
DHEA and melatonin (n-acetyl-5-methoxytrypt-
amine) have not been demonstrated to either 
significantly influence the health of older persons
or to re t a rd aging pro c e s s e s . M o re ove r, t h e re 
can be dangerous side-effe c t s . It should be 
understood that such notions are distinct from
g e ri a t ric medicine, a growing and re c o g n i ze d
f i e l d , designed to promote the health and tre a t
the illnesses of older person s .
The concept of biomarkers remains an extremely
important one. The effort to find nonlethal 
indicators of aging processes is well-defined in 
the criteria offered in the first part of this work-
shop report. Utilizing the methodology of caloric
restriction in rodent and other animal models is
one way to identify and validate such biomarkers
if they exist and, indeed, eventually a complex
panel of such biomarkers may provide increasing
means of assaying the underlying critical 
age-related biological changes.
B e cause of the high association of aging with 
d i s e a s e, and the importance of discove ring 
b i om a rk e r s , a d d i t i onal support for re s e a rch aimed
at defining measures of the biological rate of aging
should be made available beyond present funding
l evels at the Na t i onal Institutes of Health. I n d e e d ,
h a rdly more than $100 mill i on of the almost 
$18 bill i on in the NIH Fi s cal Year 2000 budget
was devoted to understanding basic processes that
a re re l evant to late life disease, and even less is
d e d i cated to understanding aging itself.
While increasing amounts of mon ey must go to
understanding the genetic and env i ronmental 
factors in health and disease, too little is dev o t e d
to re s e a rch into the biological pro p e rties of aging.
The ILC-USA thanks Dr. Huber Warner for 
his remarkable efforts in preparing this report,
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Thanks also goes to Nora O’Brien, M.A. for 
her assistance in coordinating the workshop and
preparing this document, and to Judith Estrine
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Adenine Nuclotide Translocase – an enzyme
required for transport of ATP from mitochondria
to the cytoplasm.
Alzheimer’s Disease – an aging-dependent disease
characterized by loss of memory. Risk factors
include both genetic and environmental factors.
Age of onset varies from the late 40s for patients
with early-onset genetic risk factors, to 65 and
older for most other patients.
Aminoguanidine – a compound used to reduce
non-enzymatic glycosylation of proteins.
Antioxidant – a compound and/or enzyme 
which neutralizes reactive oxygen species,
thereby reducing oxidative stress.
Apoptosis – a genetically regulated program 
leading to cell suicide.
ATP – adenosine triphosphate, the major form
of biological energy present in cells.
Biomarker (of Aging) – an age-related change
which reflects the physiological age of an 
individual, in contrast to the chronological age.
Caloric Restriction – a diet stra t e gy to limit the
ca l o ric intake, while supplying all other essential
d i e t a ry ingre d i e n t s . This extends life expectancy and
d e l ays the onset of age-related disease in ro d e n t s .
Caenorhabditis Elegans (C. elegans) – Latin name
for species of nematode, a small soil-dwell i n g
w o rm , w h i ch has been developed for biom e d i ca l
re s e a rch because of its well ch a ra c t e ri zed 
d eve l o pmental pro g ra m ; it is a useful model sys t e m
for studying aging because of its short life span.
CIS-Aconitase – an enzyme involved in the citric
acid cycle.
Citric Acid Cycle – a biochemical pathway found
primarily in mitochondria, which provides energy
for ATP synthesis.
Coenzyme Q – a component of the electron
transport system in mitochondria.
Cytochrome C – a mitochondrial protein required
for ATP synthesis; leakage of this protein into 
the cytoplasm induces apoptosis.
daf – a symbol for C. elegans mutants with 
developmental defects.
DNA Helicase – an enzyme which promotes 
s e p a ra t i on of two com p l e m e n t a ry strands of DNA .
Dehydroepiandrosterone (DHEA) – a circulating
adrenal steroid hormone which has been widely
promoted as an “anti-aging” hormone; circulating
levels decrease with age.
E u k a ryotic – organisms whose DNA is present as
ch rom o s ome pairs (includes all plants and animals).
Exonuclease – an enzyme which degrades DNA
one nucleotide at a time; s u ch enzymes are inv o lve d
in DNA re p l i ca t i on , re p a i r, and re c om b i n a t i on .
Glutamine Synthetase – an enzyme which com-
bines ammonia with glutamate, both of which are
n e u ro t ox i c , to form glutamine, w h i ch is non - t ox i c .
Growth Hormone – a hormone produced in the
pituitary which is essential for normal growth;
circulating levels decrease with age, and growth
hormone replacement has been promoted as a
possible “anti-aging” intervention.
Glossary
8-Hydroxyguanine – one of many damaged bases
found in DNA as a result of oxidative stress.
Life Expectancy – the average number of 
remaining years an individual can expect to live
at any given age.
a-lipoic Acid – a simple organic molecule con t a i n i n g
a sulfhydryl group; thus it is an antioxidant.
Longevity – the length of life of an individual,
or the average length of life of a population of
individuals.
MAPK – mitogen-activated protein kinase,
a protein involved in signal transduction.
Maximum Life Span – the longest observed life
span of an individual of any species.
Melatonin – a hormone produced in the pineal
gland, which has a role in the sleep/wake cycle;
the circulating level of melatonin decreases 
with age and melatonin replacement has been
promoted as a possible “anti-aging” intervention.
Microarry Technology – technology permitting
the assay of thousands of samples simultaneously
without individual handling.
Mitochondria – an organelle within the cell where
glucose and oxygen are metabolized to produce
ATP, the main cellular source of biological energy.
N-acetyl Cysteine – a simple organic 
molecule containing a sulfhydryl group; thus 
it is an antioxidant.
Oxidative Stress – the process whereby cellular
macromolecules are damaged by reactive oxygen
species, produced mainly in the mitochondria,
leading to dysfunction.
Pituitary – the gland which produces several 
hormones, including growth hormone.
Pply ADP-ribose Polymerase – an enzyme
involved in DNA repair.
Prolactin – a hormone produced in the pituitary
gland, acting primarily on the mammary gland 
to promote lactation.
Reporter Gene – a gene whose expression is easily
measured, often because it produces a colored
product.
Signal Transduction – the process of re l aying a
b i o l o g i cal signal from one part of a cell to another.
Single Nucleotide Polymorphism (SNP) –
a sequence difference in DNA found with 
relatively high frequency within a population.
Sulfhydryl Group – a sulfur-containing group with
antioxidant properties found in some biological
molecules.
Superoxide Dismutase (SOD) – an anti-oxidant
enzyme which converts the superoxide anion to
hydrogen peroxide.
T-lympocyte – a white blood cell produced by 
the thymus.
Thyroid Stimulating Hormone – a hormone 
produced in the pituitary gland which stimulates
growth of the thyroid.
Transcription – the process of copying the
sequence of DNA into messenger RNA.
Transgene – a gene from one organism inserted
into another.
unc – a symbol for C. elegans mutants which
appear to be “uncoordinated”.
Werner’s Syndrome – a genetic disease 
characterized by premature development of
adverse age-related changes such as cataracts,
cardiovascular disease, cancer; cataracts may
develop as early as the 20s, with average age 
of death at 45-50 years.
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The International Longevity Center–USA 
(ILC-USA) is a not-for–profit,non-partisan research, education 
and policy organization whose mission is to help individuals 
and societies address longevity and population aging in positive
and productive ways and highlight older people’s productivity and 
contributions to their families and society as a whole.
The organization is part of a multinational research and 
education consortium, which includes centers in the U.S., Japan,
Great Britain, France and the Dominican Republic.These 
centers work both autonomously and collaboratively to study how
greater life expectancy and increased proportions of older people 
impact nations around the world.
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